Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non–Small Cell Lung Cancer

Seiji Niho(Dokkyo Medical University), Tomohide Tamura(St. Luke's International Hospital), Noboru Yamamoto(Tokyo National Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Keiji Nihei(Osaka Medical and Pharmaceutical University), Kōichi Goto(National Cancer Center Hospital East), Hironobu Ohmatsu(National Cancer Center Hospital East), Ikuo Sekine(University of Tsukuba), Hidehito Horinouchi(Tokyo National Hospital), Tetsuo Akimoto(Tokyo Women's Medical University), Yuichiro Ohe(National Cancer Center), Kaoru Kubota(Nippon Medical School Hospital), Yoshinori Ito(National Cancer Center Hospital East), Kiyotaka Yoh(National Cancer Center Hospital East), Hiroshi Nokihara(Tokushima University Hospital)
American Journal of Clinical Oncology
January 17, 2014
10.1097/coc.0000000000000030
Cited by 2

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k